CytRx Doses First Patient In Phase 2 Trial With Aldoxorubicin For Brain Cancer

(RTTNews) - CytRx Corp. (CYTR), a biopharmaceutical research and development company specializing in oncology, Tuesday announced that the first patient has been dosed in the company's Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme, or GBM, a deadly form of brain cancer.

The open-label, multisite trial is designed to investigate the preliminary efficacy and safety of aldoxorubicin in patients whose tumors have progressed following prior treatment with surgery, radiation and temozolomide.

"With the dosing of the first patients we are on schedule with this important Phase 2 GBM trial, and look forward to reporting preliminary results in the second half of this year," said CytRx President and CEO Steven Kriegsman.

The company noted that the primary objective of this Phase 2 trial is to determine progression-free survival and overall survival according to RANO Working Group Criteria.